Skip to main content
. Author manuscript; available in PMC: 2018 Apr 18.
Published in final edited form as: Clin Cancer Drugs. 2017;4(2):122–128. doi: 10.2174/2212697x04666170817123425

Table 3.

DPD status category according to UH2/U ratio value and subsequent dose tailoring.

DPD status UH/U ratio Theoretical adaptative dosing
Extensive metabolizers (EM) > 4 Standard 5-FU dosing
Poor metabolizers (PM) Grey-zone patients [3 – 4] Alert for reduced activity, without systematic dose reduction
mildly DPD deficient ]2 – 3[ 20% dose reduction
intermediary DPD deficient ]1 – 2] 30% dose reduction
profoundly DPD deficient ]0.5 – 1] 50% dose reduction
completely DPD deficient < 0.5 or UH2 not detectable upon HPLC analysis 5-FU precluded